Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease). The aim of this trial is to establish the clinical utility of imple

Trial Details

NCT ID
NCT07673861
Phase
NA
Sponsor
Royal Marsden NHS Foundation Trust
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Marsden360 ctDNA test and GTAB review
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • All cohorts:
  • Age ≥18 years old
  • Ability to provide written informed consent
  • Presence of metastatic or unresectable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →